A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC)

2023-505163-37-00 Protocol WO42758 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 1 Oct 2021 · Status Ongoing, recruiting · 5 EU/EEA countries · 26 sites · Protocol WO42758

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 309
Countries 5
Sites 26

Metastatic Colorectal Cancer

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
1 Oct 2021 → ongoing
Decision date (initial)
2024-07-08
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-505163-37-00
EudraCT number
2021-001207-33

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic Colorectal Cancer

VersionLevelCodeTermSystem organ class
27.0 LLT 10052362 Metastatic colorectal cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

5 EU/EEA countries · 26 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ongoing, recruiting 3 2
Germany Ongoing, recruiting 31 8
Italy Ongoing, recruiting 20 6
Poland Ongoing, recruiting 3 4
Spain Ongoing, recruiting 12 6
Rest of world
Korea, Republic of, Australia, United States, Canada, Taiwan, United Kingdom
240

Investigational sites

Denmark

2 sites · Ongoing, recruiting
Rigshospitalet
Onkologisk afdeling, Blegdamsvej 9, 2100, Copenhagen Oe
Herlev og Gentofte Hospital
Onkologisk afdeling, Borgmester Ib Juuls Vej 1, 2730, Herlev

Germany

8 sites · Ongoing, recruiting
Charite Universitaetsmedizin Berlin KöR
Hämatologie/Onkologie und Tumorimmunologie, Augustenburger Platz 1, Wedding, Berlin
Katholisches Klinikum Bochum gGmbH
Hämatologie und Onkologie, Gudrunstrasse 56, Grumme, Bochum
Universitaetsklinikum Duesseldorf AöR
Klinik für Gastroenterologie Infektologie u. Hepatologie, Moorenstrasse 5, Bilk, Duesseldorf
Universitaetsklinikum Ulm AöR
Klinik für Innere Medizin I, Albert-Einstein-Allee 23, Eselsberg, Ulm
Asklepios Kliniken Hamburg GmbH
Hämatologie, Onkologie, Palliativmedizin und Rheumatologie, Paul-Ehrlich-Strasse 1, Othmarschen, Hamburg
SLK-Kliniken Heilbronn GmbH
Innere Medizin III, Schwerpunkt Häma./Onko./Palliativm., Am Gesundbrunnen 20-26, Neckargartach, Heilbronn
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
Klinik und Poliklinik, Fetscherstrasse 74, Johannstadt-Nord, Dresden
Klinikum der Universitaet Muenchen AöR
Medizinische Klinik und Poliklinik III, Marchioninistrasse 15, Hadern, Munich

Italy

6 sites · Ongoing, recruiting
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Oncologia Medica, Via Piero Maroncelli 40, 47014, Meldola
Fondazione IRCCS Istituto Nazionale Dei Tumori
S.C. Oncologia Medica 1, Via Giacomo Venezian 1, 20133, Milan
Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli
Oncologia Medica, Via Sergio Pansini 5, 80131, Naples
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
UOC Fase 1, Largo Francesco Vito 1, 00168, Rome
ASST Grande Ospedale Metropolitano Niguarda
S.C. Oncologia Falck, Piazza Dell'ospedale Maggiore 3, 20162, Milan
Istituto Oncologico Veneto
Oncologia Medica 1, Via Gattamelata 64, 35128, Padova

Poland

4 sites · Ongoing, recruiting
Uniwersytecki Szpital Kliniczny W Poznaniu
Oddział Kliniczny Onkologii Klinicznej i Doświadczalnej, Ul. Augustyna Szamarzewskiego 84, 60-569, Poznan
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Oddział Badań Wczesnych Faz, Ul. Wilhelma Konrada Roentgena 5, 02-781, Warsaw
Uniwersyteckie Centrum Kliniczne
Ośrodek Badań Klinicznych Wczesnych Faz, Ul. Mariana Smoluchowskiego 17, 80-214, Gdansk
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie
Oddział Kliniczny Onkologii, Ul. Mikolaja Kopernika 50, 31-501, Cracow

Spain

6 sites · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Oncologia, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Oncologia, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Clinico Universitario De Valencia
Oncologia, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Puerta De Hierro De Majadahonda
Oncología, Calle De Manuel De Falla 1, 28222, Majadahonda
Hospital Clinico Universitario Lozano Blesa
Oncología, Avenida De San Juan Bosco 15, 50009, Zaragoza
Hospital Universitario Donostia
Oncología, Pasealeku Doct. Begiristain 109, 20014, Donostia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2023-12-01 2023-12-08
Germany 2025-06-17 2025-06-17
Italy 2021-10-01 2021-10-06
Poland 2023-09-11 2023-12-04
Spain 2021-10-19 2021-12-09

Application history

8 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-31 Denmark Acceptable
2024-07-07
2024-07-08
2 SUBSTANTIAL MODIFICATION SM-1 2024-08-22 Denmark Acceptable
2024-10-31
2024-10-31
3 SUBSTANTIAL MODIFICATION SM-2 2024-11-25 Denmark Acceptable
2025-02-26
2025-02-26
4 NON SUBSTANTIAL MODIFICATION NSM-1 2025-04-02 Denmark Acceptable
2025-02-26
2025-04-02
5 SUBSTANTIAL MODIFICATION SM-3 2025-04-09 Denmark Acceptable 2025-05-09
6 SUBSTANTIAL MODIFICATION SM-4 2025-05-26 Denmark Acceptable
2025-07-31
2025-07-31
7 SUBSTANTIAL MODIFICATION SM-5 2025-11-21 Denmark Acceptable
2026-02-03
2026-02-04
8 SUBSTANTIAL MODIFICATION SM-6 2026-03-19 Denmark Acceptable
2026-05-19
2026-05-19